1 | INTRODUCTION

Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide.\(^1\) Old age, bad lifestyle and hereditary diseases are risk factors for CRC.\(^2\) Another risk factor is inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC).\(^3\) To date, treatments for CRC include some combination of surgery, radiation therapy, chemotherapy and targeted therapy.\(^4\) However, due to the inherent ability of CRC to become chemotherapy and radiation resistant, the combined-modality therapy has failed to universally improve patients’ prognosis.\(^4\) In tumour therapy, apoptosis tolerance is an important mechanism of tumour resistance to treatment.\(^5\) Autophagy is able to prevent drugs-induced apoptosis and promote tumour resistance.\(^6\) Nevertheless, autophagic cell death may also be a mode of death for apoptosis-tolerant tumour cells.\(^7\) Therefore, autophagy has a dual effect on cancer progression and cancer treatment.

Autophagy is an evolutionarily conserved process that involves degradation of eukaryotic cellular components.\(^8\) Specifically, damaged or redundant proteins and dysfunctional cellular components are engulfed in the separation membrane and then extended into double-membrane autophagosomes, followed by fusion of double-membrane autophagosomes with lysosomes to form autophagosomes.\(^9\) It is subsequently degraded into simple ingredients to meet the energy and anabolic needs of the cells.\(^10\) Remarkably, the formation of autophagosome is regulated by autophagy-related genes (ATGs), such as ATG12, ATG5 and microtubule-associated protein light chain 3 (LC3).\(^11\) Autophagy is a stress response required for cellular survival.\(^12\) More extensive studies showed that autophagy mediates tumour survival by providing nutrients to stressed cancer cells.\(^13\) However, a report has demonstrated that activation of autophagy can result in cell death and inhibition of tumour progression.\(^14\)

A growing body of evidence suggests that anti-cancer therapies such as chemotherapy, radiation and targeted therapies can induce...
Effects of Autophagy and Mirna on Chemotherapy of CRC

In general, chemotherapeutic drugs are used as an adjunct to CRC. Chemical drugs repress cancer progression by preventing the cell cycle and inducing apoptosis. Oxaliplatin (OXA) is the third-generation platinum compound and the first platinum compound to achieve a significant effect in the treatment of CRC. Nevertheless, despite the rapid reduction in tumour size after chemotherapy, cancer cells often develop resistance to OXA, leading to subsequent cancer recurrence and metastasis. Similarly, 5-fluorouracil (5-FU) is a widely used first-line systemic chemotherapy drug. Its clinical therapeutic effect varies greatly among individuals, and drug resistance is considered to be the main reason for its failure to treat CRC. Some reports have indicated that the resistance of chemotherapeutics is highly correlated with the cytoprotective effects of autophagy. In most cases, sustained drug exposure can induce an imbalance in the apoptotic pathway and lead to resistance to apoptosis. Additionally, chemotherapeutic drugs activate autophagy to protect cells from stress-induced damage, thus promoting cancer cell resistance and reducing the efficiency of most anti-cancer drugs. Recently, some autophagy inhibitors have been shown to improve the efficacy of chemotherapeutic drugs for cancer treatment. For example, inhibition of autophagy by 3-methyladenine (3-MA) and hydroxychloroquine (HQC) can promote 5-FU-induced apoptosis in CRC cells. Therefore, enhancing apoptosis of cancer cells by inhibiting cytoprotective autophagy may be a promising strategy for adjuvant chemotherapy in CRC.

2 | Effects of Autophagy and Mirna on Chemotherapy of CRC

In vitro and in vivo experiments have illustrated that miR-22 can inhibit autophagy and promote apoptosis to increase the sensitivity of 5-FU treatment in CRC cells. B-cell translocation gene 1 (BTG1), a new target of miR-22, is a member of the anti-proliferative gene family that regulates cell growth and differentiation and can reverse the inhibition of miR-22-induced autophagy. Therefore, miR-22 may be considered as an important conversion factor between autophagy and apoptosis, and the sensitivity of 5-FU may be regulated by post-transcriptional silencing of BTG1. It has been reported that p53 is involved in apoptosis induced by 5-FU and other chemotherapeutic agents, including DNA damage and induction of pro-apoptotic genes such as Fas. Because p53-mutant is less capable of inducing apoptosis, p53-mutant CRC cells are more resistant to chemicals than p53-wide-type CRC cells. The findings indicate that the mutant p53 regulates protective autophagy caused by chemotherapy or radiotherapy and has clinical implications. Mammalian target of rapamycin (mTOR) significantly modulates the competition between autophagy and apoptosis, and its expression is regulated by miR-338-3p. It was shown that the miR-338-3p-mTOR-autophagy is regulated in a p53-dependent manner and involved in the response to 5-FU treatment. Chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor C-X-C chemokine receptor type 4 (CXCR4) play important roles in cancer growth, metastasis and invasion. MiR-125b is up-regulated by activation of the CXCL12/CXCR4 axis, which in turn enhances CXCR4 expression. Study showed that miR-125b confers 5-FU resistance by increasing autophagy, displaying the increase of Beclin 1, microtubule-associated protein light chain 3 II (LC3-II) cleavage and autophagosome formation.

It was observed that overexpression of miR-409-3p sensitizes CRC cells to OXA and restraints chemotheraphy-induced autophagy in a manner that depends on Beclin 1, suggesting that miR-409-3p is able to enhance the chemosensitivity of CRC cells by inhibiting Beclin 1-mediated autophagy. Furthermore, expression of mir-34a is down-regulated in OXA-resistant cells, whereas transfection of mir-34a mimics enhances the efficacy of OXA by repressing autophagy and enhances the efficacy of OXA against OXA-resistant CRC cells. At the same time, the autophagy inhibitor 3-MA enhances the pro-apoptotic effect of OXA-resistant cells. These evidences have...
implicated that activation of autophagy protects CRC cells from OXA-induced apoptosis by suppressing miR-34a expression. 56 Wu et al identified that miR-27b-3p inhibited the expression of ATG10 at the post-transcriptional level, thus inhibiting autophagy to sensitize CRC cells to OXA in vivo and in vitro. 57

In addition, emerging evidence demonstrated that chemotherapy against tumours require the involvement of the immune system. 58 Once the tumour immunogenic cell death (ICD) is induced in chemotherapy, the prognosis is good. 59 However, the formation of autophagy is thought to promote immune evasion. 59 Damage-associated molecular patterns (DAMPs), which are recognized by receptors on the surface of immune cells, are released by autophagic cell death, apoptotic and necrotic tumour cells. They can initiate an adaptive immune response either directly or indirectly. 60 It determines to some extent whether cell death is ICD or tolerogenic cell death. 61 Chemotherapy-induced ICD is able to trigger DAMPs, such as the kinetics of choleteric surface exposure, the secretion of adenosine tri-phosphate (ATP) and high mobility group box 1 (HMGB1). 62 Evidence suggested that high expression of miR-27a induced by chemotherapeutic drugs disrupts DAMP, silences apoptotic pathways, and enhances cell growth and survival potential. Moreover, the high expression of miR-27a is involved in liver metastasis and worse prognosis. 63 Similarly, CRC cells expressing low levels of miR-27a undergoing drug-induced ICD can stimulate efficient maturation of dendritic cells and secretion of cytokines, promoting immune activation and cell death. 63 Notably, miR-27a also reversely regulates autophagy, and apoptosis and autophagy are oriented in the same direction in cell models. 64,65 Consequently, it is of great significance to make a further study on the role of autophagy in the chemoresistance of CRC cells.

3 | EFFECTS OF AUTOPHAGY AND MI RNA ON CHEMOTHERAPY OF CRC STEM CELLS

It is reported that miRNAs are capable of destroying the ability of autophagy to increase the chemosensitivity of CRC stem cells and inhibit the invasion. 65,66 Cancer stem cells (CSCs) are cancer cells that have characteristics associated with normal stem cells, and it has the ability to differentiate into all cell types in a particular cancer sample. 67 Since the small subpopulation of CSCs persists in tumours, CSCs can cause tumour resistance, relapse and metastasis through self-renewal and differentiation. 68,69 The autophagy mechanism of CRC stem cells has been identified as one of the major contributors to CRC resistance to chemotherapy and recurrence and metastasis. 39 Mothers against decapentaplegic homolog 2 (Smad2), a downstream gene of the transforming growth factor beta (TGF-β) signalling pathway, is associated with increased TGF-β levels and poor prognosis, which leads to increased survival of metastatic cells and organ colonization in advanced CRC. 70 In the experiment, hsa-miR-140-5p directly inhibits the expression of Smad2 and regulates ATG12, and then it suppresses cell invasion, proliferation and induced cell cycle arrest. In addition, hsa-miR-140-5p disrupts autophagy and inhibits the growth and metastasis of CRC stem cells in vivo and in vitro. 71 Furthermore, it is showed that miR-502 induces cell cycle arrest at both G1 and G2 checkpoints and is more prominent in wild-type p53 HCT116 cells, and it can also restrain autophagy and reduce tumour growth by targeting Ras-related protein RAB18. 72 These findings provide new insights into the effects of autophagy and miRNA on CRC chemotherapy.

4 | EFFECTS OF AUTOPHAGY AND MI RNA ON RADIOThERAPY OF CRC

Recent studies have suggested that deregulation of autophagy is related to radiation resistance of tumours, and miRNA expression patterns are involved in the modification of radiation therapy. 73,74 After irradiation (IR) therapy, the levels of miR-214 in human CRC cells and peripheral blood are significantly decreased, while autophagy in CRC cells is induced. 25 Further experiments showed that miR-214 is able to inhibit ATG12-induced autophagy and increase apoptosis, thus significantly increasing the radiosensitivity of CRC. 25 These results indicate that miR-214 achieves radioresistant effect by targeting autophagy-related gene ATG12. 25,75 However, contrary experimental results have shown that increased abundance of miR-183-5p and decreased ATG5 levels are associated with poor prognosis of CRC, and miR-183-5p enhances radioresistance of CRC by directly targeting ATG5. 76 Thus, further and deeper research is needed to clarify the role of miRNA and autophagy on radiotherapy in CRC.

Fibroblasts maintain the structural integrity of connective tissue by continuously secreting precursors of the extracellular matrix. 77 Cancer-associated fibroblast (CAF) secretes growth factors and interacts with tumour cells to provide nutrient support for tumour growth and enhance tumour metabolic regulation and immunity reaction. 78 A study by Yang et al revealed that up-regulation of miR-31 can inhibit the expression of autophagy-related genes Beclin 1, ATG, damage-regulated autophagy modulator (DRAM) and LC3, and it can increase the radiosensitivity of CRC cells co-cultured with CAF. 79

5 | EFFECTS OF AUTOPHAGY AND MI RNA ON METABOLISM AND HYPOXIA OF CRC

Compared with normal cells, cancer cells exhibit a metabolic phenotype characterized by increased glycolysis and significantly alter nutrient utilization, regardless of oxygen availability. The phenomenon termed the Warburg effect. 80 Since the survival of cancer cells mainly depends on the rate of high glucose consumption and the elevation of glycolysis, the Warburg effect and glucose metabolism are important strategies for cancer treatment. 81 In mammals, glucose metabolism can be regulated by controlling the expression of pyruvate kinase isozymes M1/M2 (PKM1/M2). 82 Abnormal expression of PKM1/M2 is essential for maintaining the growth of cancer cells. 83 The ectopic expression of miR-124 induces apoptosis and autophagy...
The knock-down of polypyrimidine tract-binding protein 1 (PTB1, also known as heterogeneous nuclear ribonucleoprotein A1) is able to induce drastically apoptotic cell death which indicates PTB1 acts as an oncogene. In vitro experimental studies confirmed that miR-124 targets PTB1 and regulates the ratio of PKM1/PKM2 to inhibit CRC growth. Furthermore, miR-18a induces apoptosis of CRC cells by directly binding to the oncogene heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) via autophago-lysosomal pathway.

Due to the rapid proliferation of tumour cells, hypoxia within the tumour is one of the most important features of solid tumours. Hypoxia is a well-known inducer of autophagy which leads to cancer cells resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor 1-alpha (HIF-1α) is an important factor regulating cell responses to hypoxia. Hypoxia-induced autophagy is also involved in HIF-1α-mediated cell survival mechanisms. The study found that miR-210 is continuously up-regulated in CRC and promotes CRC migration and invasion. Hypoxia induces HIF-1α and its downstream target miR-210, which is able to restrain the expression of B-cell lymphoma 2 (Bcl-2) and enhance autophagy, thereby contributing to the radioresistance of CRC cells. Bcl-2 exerts a dual function as an anti-apoptotic, anti-autophagic protein, and may be related to reactive oxygen species (ROS) levels. Similarly, under conditions of nutrient starvation, low levels of Bcl-2 phosphorylation initially occur and survival are promoted by activation of autophagy, while higher levels of Bcl-2 phosphorylation accelerate apoptosis as prolonged starvation time. Besides, a previous study has reported that miR-20a is significantly down-regulated under hypoxia in CRC cells, and overexpression of miR-20a directly targets ATG5 and FIP200 (focal adhesion kinase family kinase-interacting protein of 200 KDa) and alleviates hypoxia-induced autophagy. Consequently, a better understanding the mechanisms of miRNA and autophagy in metabolism and hypoxia may be of potential value in improving the effectiveness of CRC treatment.

6 | EFFECTS OF AUTOPHAGY AND MIRNA ON INFLAMMATORY BOWEL DISEASE

IBD is a group of inflammatory disorders of the colon and small intestine, of which CD and UC are the major types of inflammatory bowel disease. Due to the presence of symptoms such as abdominal pain, vomiting, diarrhoea, rectal bleeding and anaemia in IBD, it seriously affects the life quality of patients. CRC is a recognized
The rise. The onset of IBD is primarily due to an abnormal immune response against luminal antigens and microbiota. Studies have pointed out that miRNA is capable of regulating autophagy-related genes involved in the pathogenesis of IBD, such as ATG5, autophagy-related gene 16-like 1 (ATG16L1), autophagy-related 2 homolog B (ATG2B) and immunity-related GTPase family M protein (IRGM), while autophagy regulates miRNA homeostasis by degrading miRISC. MiR-142-3p targets ATG16L1 and reduces the autophagic activity resulting from starvation-induced cell death and apoptosis in CRC cells. At the same time, miR-142-3p can inhibit inflammatory bowel disease protein 1 (IBD1)-dependent autophagy and effectively down-regulate interleukin 8 (IL-8) mRNA expression, further suggesting miR-142-3p exerts autophagy-related effects in intestinal inflammation and CD. Highly expressed miR-93 and miR-106b can also target ATG16L1 in active CD to reduce autophagosome formation. Aylia et al extracted the total RNA from peripheral blood mononuclear cells of CD and UC patients and found miR-874-3p is the most differentially expressed. They further confirmed that miR-874-3p dysregulates autophagy by targeting ATG16L1. Above evidences have implicated unique panels of miRNAs in blood and tissue distinguishing CD and UC in varying regimes of disease activity. Additionally, both miR-130a and miR-30c are dysregulated in CD and considered to be key regulators of the autophagy pathway in innate immunity. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) protein is involved in the control of immune and inflammatory responses, developmental processes, cellular growth and apoptosis. It was demonstrated that enhanced autophagosome activity is effectively able to attenuate NF-κB-mediated inflammation. Experiments indicated that there is abnormal activation of NF-κB pathway in miR-143 overexpressed or ATG2B-depleted CRC cell lines, suggesting that miR-143 may suppress autophagy and increase inflammation reaction of the NF-κB pathway in CD by targeting ATG2B. Therefore, further researches should be conducted to promote the clinical application of miRNAs in IBD. (Figure 1) (Table 1).

### TABLE 1 MiRNAs regulating autophagy under different CRC conditions

| Chemotherapy of CRC | Potential target of miRNA | Effect of miRNA on autophagy |
|---------------------|---------------------------|-----------------------------|
| miR-22              | BTG1                       | Inhibition                  |
| miR-33b-3p          | mTOR                      | Inhibition                  |
| miR-125b            | CXCL12/CXCR4              | Promotion                   |
| miR-409-3p          | Beclin 1                   | Inhibition                  |
| miR-34a             | ATG4B                      | Inhibition                  |
| miR-27b-3p          | ATG10                      | Inhibition                  |
| miR-27a             | PINK1                      | Inhibition                  |
| miR-140-5p          | ATG12                      | Inhibition                  |
| miR-502             | RAB1B                      | Inhibition                  |
| miR-214             | ATG12                      | Inhibition                  |
| miR-183-5p          | ATG5                       | Inhibition                  |
| miR-31              | Beclin 1, ATG, LC3         | Inhibition                  |
| miR-124             | PTB1                       | Promotion                   |
| miR-18a             | hnRNP A1                   | Promotion                   |
| miR-210             | Bcl-2                      | Promotion                   |
| miR-20a             | ATG5 and FIP200            | Inhibition                  |
| miR-142-3p          | ATG16L1                    | Inhibition                  |
| miR-142-3p          | IBD1                       | Inhibition                  |
| miR-93              | ATG16L1                    | Inhibition                  |
| miR-106b            | ATG16L1                    | Inhibition                  |
| miR-874-3p          | ATG16L1                    | Inhibition                  |
| miR-130a            | ATG5 ATG16L1               | Inhibition                  |
| miR-30c             | ATG5 ATG16L1               | Inhibition                  |
| miR-143             | ATG2B                      | Inhibition                  |

Abbreviation: PINK1, PTEN-induced putative kinase 1.

### DISCUSSION AND CONCLUSION

Autophagy may perform a dual function in the progression of CRC. As described above, the autophagy inhibitors 3-MA and HCQ are able to inhibit autophagy, promote 5-FU-induced CRC cell apoptosis and increase patient sensitivity to chemotherapy. However, some findings have revealed that the autophagy inducers rapamycin can reduce the migration capacity of CRC cells. Many miRNAs regulate autophagy under CRC stress conditions, including chemotherapy, radiation therapy, nutrient and hypoxia.

MiRNAs are thought to increase/decrease the chemosensitization or radiosensitization by regulating the level of autophagy in CRC cells, which has potential value for the treatment of CRC. For example, miR-22 restrains autophagy and promotes apoptosis, thereby improving the sensitivity of 5-FU treatment in CRC cells. In contrast, miR-183-5p directly targets ATG5 to enhance the radioresistance of CRC.

Noticeably, recent studies have reported that several miRNAs have been shown to target autophagy-associated proteins in other tumours, regulating the occurrence and development of tumours. For instance, miR-543 is a cancerous suppressor in ovarian cancer, inhibiting the expression of twist family bHLH transcription factor 1 (TWIST1). TWIST1 is not only a vital protein involved in tumour metastasis and invasion, but also its stability is modulated by p62, the substrate of autophagy. However, miR-543 is a cancer-promoting factor in CRC, which may be involved in regulating autophagy through the mTOR pathway to affect the...
effect of chemotherapy.\textsuperscript{116-118} MiRNA-23b also has an inhibitory effect on non-small cell carcinoma by inhibiting RUNX family transcription factor 2 (Runx2),\textsuperscript{119} while Runx2 has been shown to promote autophagy by increasing the acetylation of microtubule α-tubulin subunits in advanced breast cancer cells.\textsuperscript{120} MiRNA-23b in CRC promoted cell migration by down-regulating forkhead box P2 (FOX2).\textsuperscript{121} MiRNA-142-3p suppresses cellular proliferation and migration via directly acting on Rac family small GTPase 1 (Rac1) in bladder cancer.\textsuperscript{122} It has been reported that Rac1 can regulate autophagy.\textsuperscript{123} MiRNA-142-3p was found to function as a cancer-promoting factor through Rac1 in CRC. By bioinformatics prediction, Rac1 has a miR-142-3p binding site in its 3’-UTR.\textsuperscript{124} However, there is a positive correlation between Rac1 and miRNA-142-3p in CRC, and the authors believe that miRNA-142-3p may function through activating Rac1 indirectly.\textsuperscript{126} As can be seen from the above, although it has been found that miR-543, miRNA-23b and miRNA-142-3p are aberrantly expressed in CRC, the mechanism is not completely clear. There is a great possibility that it is related to autophagy, and more research is needed to explore this mechanism.

Since miRNA can be used as an influencing factor of autophagy, it may be a feasible research direction to study the upstream regulatory pathways of miRNA such as circular RNA (circRNA) and long non-coding RNA (lncRNA). In the previous study, circHIPK3 which promoted OXA resistance in CRC through autophagy by sponging miR-637 via miR-637/STAT3/Bcl-2/Becn1 axis is up-regulated in tissues from chemoresistant and recurrent CRC patients and correlated with tumour size, regional lymph node metastasis, distant metastasis and survival.\textsuperscript{125} Furthermore, lncRNAs have been reported to regulate chemoresistance.\textsuperscript{126} LncRNA small nucleolar RNA host gene 6 (SNHG6) is able to promote 5-FU resistance through unc-51 like autophagy activating kinase 1 (ULK1)-induced autophagy by sponging miR-26a-5p in CRC cells.\textsuperscript{127} It has been proved that lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), which promotes CRC chemotherapy resistance,\textsuperscript{128} can affect the expression of enhancer of zeste homolog 2 (EZH2) by up-regulating miR-363-3p,\textsuperscript{129} and EZH2 is an essential regulatory factor that phosphorylates histone H2B and then increases autophagy.\textsuperscript{130} LncRNA H19 might work as a competing endogenous RNA (ceRNA) to sponge miR-194-5p and conferred 5-FU resistance in CRC by promoting sirtuin1 (SIRT1)-mediated autophagy.\textsuperscript{131} Moreover, lncRNA KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) enhances the chemoresistance of OXA in CRC by targeting the miR-34a/ATG4B pathway.\textsuperscript{132} The therapeutic strategies of CRC besides exploring how miRNA and autophagy regulate the chemical sensitivity of CRC to drugs, the exploration of synthetic compounds such as miRNA mimic/inhibitor and natural component such as the anti-tumour agent inositol hexaphosphate (IP6) which down-regulated miR-155 to modulate the autophagy-related protein like HIF-1α may also be a new approach.\textsuperscript{132}

It is important to probe into the molecular mechanism of CRC treatment, but the method of detecting the effect of treatment cannot be ignored. In recent years, liquid biopsy, such as detection of circulating miRNAs in plasma and serum, has become a research hotspot, and detection of miRNAs in serum exosomes is also expected to become a predictive marker of chemoresistance in advanced CRC.\textsuperscript{133} However, it may also encounter problems of high cost or poor repeatability. Absolutely, future fundamental and clinical researches are required considering these limitations.

Additionally, IBD is a chronic complex disorder caused by a variety of factors.\textsuperscript{134} As mentioned above, autophagy-related genes are regulated by multiple miRNAs in IBD and play a role in regulating inflammation, which is a complex network.\textsuperscript{104,105} Therefore, miRNA can be regarded as a new diagnostic marker and therapeutic target. These evidences reveal underlying mechanisms of the pathophysiology and provide new diagnostic and therapeutic targets in IBD.

MiRNAs play an important role in the occurrence and development of CRC by regulating the level of autophagy in CRC cells. The exact mechanisms by which miRNAs-regulated autophagy controls cancer occurrence and development have not been established. It appears to be dependent on the tumour microenvironment with a dual role of tumour promotion and inhibition. In fact, in addition to miRNA regulating autophagy, there are a few reports suggesting that autophagy may affect miRNA homeostasis.\textsuperscript{135} Autophagy has been found to degrade the enzymes Dicer and AGO2 during miRNA processing and maturation in several tumours.\textsuperscript{102,136-138} However, this phenomenon has not been reported in CRC. Therefore, it is necessary to determine how the autophagy mechanism exerts a dual effect in the CRC. Further research is needed to better understand the relationship between miRNA and autophagy in CRC and to produce potentially beneficial drugs for the prognosis and treatment of CRC.

ACKNOWLEDGEMENTS
None.

CONFLICT OF INTEREST
None.

AUTHORS’ CONTRIBUTIONS
JLL and QLH drafted the manuscript. YTY, XL and ZQL were involved in data gathering. WZ revised the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID
Wei Zhu \textsuperscript{https://orcid.org/0000-0002-1217-1718}

REFERENCES
1. Sung JJY, Ng SC, Chan FKL, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64:121-132.
2. Theodoratou E, Timofeeva M, Li X, et al. Nature, Nurture, and Cancer Risks: Genetic and Nutritional Contributions to Cancer. Annu Rev Nutr. 2017;37:293-320.

3. Adami H-O, Brethauer M, Emilsson L, et al. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016;65:889-893.

4. Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235-246.

5. O’Connell J, Bennett MW, Nally K, et al. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumour-immune conflict. Ann NY Acad Sci. 2000;910(178–192):193-195.

6. Galluzzi L, Bravo-San Pedro JM, Levine B, et al. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017;16:487-511.

7. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev. 2011;25:1999-2010.

8. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-eating: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15:81-94.

9. Hou W, Zhang Q, Yan Z, et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 2017;8:e2633.

10. Pyo JO, Nah J, Jung YK. Molecules and their functions in autophagy. EXP MOL MED. 2012;44:73-80.

11. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagy. Annu Rev Cell Dev Biol. 2011;27:107-132.

12. Zhou H, Yuan M, Yu Q, et al. Autophagy regulation and its role in gastric cancer and colorectal cancer. Cancer Biomark. 2016;17:1-10.

13. Gugnoni M, Sancisi V, Manzotti G, et al. Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer. Cell Death Dis. 2016;7:e2520.

14. Eldgindy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin 1 promotes autophagic cell death and limits clonogenic survival. Mol Cell. 2011;42:23-35.

15. Zou Z, Yuan Z, Zhang Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8:1798-1810.

16. Zeng W, Liu P, Pan W, et al. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356:263-267.

17. Chaouchoua H, Ohnesepi P, Toulan M, et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol. 2011;99:287-292.

18. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728-741.

19. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.

20. Wonyie W, Jumansong A, Chamgramoel Y, et al. 5’-UTR and 3’-UTR Regulation of MICB Expression in Human Cancer Cells by Novel microRNAs. Genes (Basel). 2017;8.

21. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203-222.

22. Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol. 2012;44:733-736.

23. Sibony M, Abdullah M, Greenfield L, et al. Microbial Disruption of Autophagy Alters Expression of the RISC Component AGO2, a Critical Regulator of the miRNA Silencing Pathway. Inflamm Bowel Dis. 2015;21:2778-2786.

24. Yao Z, Xie F, Li M, et al. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 2017;8:e2633.

25. Hu JL, He CY, Lan XL, et al. Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer. Oncogenesis. 2018;7:16.

26. Wang Y, Zhang S, Dang S, et al. Overexpression of microRNA-216a inhibits autophagy by targeting regulated MAP15 in colorectal cancer. Oncotargets Ther. 2019;12:4621-4629.

27. Liao D, Li T, Ye C, et al. miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells. Exp Ther Med. 2018;15:1712-1717.

28. Qased AB, Yi H, Liang N, et al. MicroRNA-18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells. Mol Med Rep. 2013;7:559-564.

29. Chu C-A, Lee C-T, Lee J-C, et al. miR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway. Ebiomedicine. 2019;43:270-281.

30. Yu X, Shi W, Zhang Y, et al. CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer. Sci Rep. 2017;7:42226.

31. Han J, Li J, Tang K, et al. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin. Exp Cell Res. 2017;360:328-336.

32. Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1-10.

33. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998;16:2739-2744.

34. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-487.

35. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338.

36. Touil Y, Igoudjil W, Corvaisier M, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res. 2014;20:837-846.

37. Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35(Suppl):S78-S103.

38. Lubner SJ, Lo Conte NK, Holen KD, et al. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:157-161.

39. Wu S, Wang X, Chen J, Chen Y. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Biochem Biophys Res Commun. 2013;434:898-903.

40. Yang H-Z, Ma YI, Zhou Y, et al. Autophagy contributes to the enrichment and survival of colorectal stem cells under oxaliplatin treatment. Cancer Lett. 2015;361:128-136.

41. Hou J, Xu G, Wang Y, et al. Oxidative stress induced autophagy in cancer associated fibroblast enhances proliferation and metabolism of colorectal cancer cells. Cell Cycle. 2017;16:73-81.

42. Maycotte P, Aryal S, Cummings CT, et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012;8:200-212.

43. Li J, Hou NI, Faried A, et al. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer. 2010;46:1900-1909.

44. Zhang H, Tang J, Li C, et al. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett. 2015;356:781-790.

45. Rouault JP, Rimokh R, Tessa C, et al. BTG1, a member of a new family of antiproliferative genes. Embo J. 1992;11:1663-1670.
47. Chen J. The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harb Perspect Med. 2016;6:a26104.

48. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003;21:271-276.

49. Sui X, Kong NA, Wang X, et al. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep. 2014;4:4694.

50. He C, Li L, Guan X, et al. Mutant p53 Gain of Function and Chemosensitivity: The Role of Mutant p53 in Response to Clinical Chemotherapy. Chemotherapy. 2017;62:43-53.

51. Rosenfeldt MT, O’Prey J, Morton JP, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504:296-300.

52. Park YL, Kim HP, Cho YW, et al. Activation of WNT/beta-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. Int J Cancer. 2019;144:389-401.

53. Zeelenberg IS, Ruuls-Van SL, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003;63:3833-3839.

54. Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6:1347-1361.

55. Li Y, Li C, Li D, et al. lncRNA KCNQ1OT1 enhances the chemoresistance of colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther. 2019;12:2649-2660.

56. Sun WU, Li J, Zhou L, et al. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Theranostics. 2020;10:1981-1996.

57. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.

58. Tan S, Shi H, Ba M, et al. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin 1-mediated autophagy. Int J Mol Med. 2016;37:1030-1038.

59. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670-5677.

60. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860-875.

61. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3-12.

62. Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology. 2014;3:e28131.

63. Colangelo T, Polcaro G, Ziccardi P, et al. The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in colorectal cancer cells. Cell Death Dis. 2016;7:e2108.

64. Kim J, Fiesel FC, Belmonte KC, et al. miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Mol Neurodegener. 2016;11:55.

65. Hua X, Xu J, Deng XU, et al. New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer. Cancer Lett. 2018;436:38-51.

66. Jones MF, Harra T, Francis P, et al. The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. Proc Natl Acad Sci U S A. 2015;112:E1550-E1558.

67. Nassar D, Blanpain C. Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016;11:47-76.

68. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.

69. Park EY, Chang EunSun, Lee EJ, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014;74:7573-7582.

70. Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571-584.

71. Zhai H, Fesler A, Ba Y, et al. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget. 2015;6:19735-19746.

72. Zhai H, Song B, Xu X, et al. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013;32:1570-1579.

73. Luo M, Ding L, Li Q, Yao H. miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha. Breast Cancer-Tokyo. 2017;24:673-682.

74. Zhu R-X, Song C-H, Yang J-S, et al. Downregulation of AATK mediates microRNA-558-induced resistance of A549 cells to radiotherapy. Mol Med Rep. 2016;14:2846-2852.

75. Salim H, Akbar NS, Zong D, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012;107:1361-1373.

76. Zheng S, Zhong Y-F, Tan D-M, et al. miR-183-5p enhances the radioresistance of colorectal cancer by directly targeting ATG5. J Biosci. 2019;44.

77. Weissman-Shomer P, Fry M. Chick embryo fibroblasts senesce in vitro: pattern of cell division and life span as a function of cell density. Mech Ageing Dev. 1975;4:159-166.

78. Tommelen J, Verset L, Boterberg T, et al. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol. 2015;5:63.

79. Yang X, Xu X, Zhu J, et al. miR-31 affects colorectal cancer cells by inhibiting autophagy in cancer-associated fibroblasts. Oncotarget. 2016;7:79617-79628.

80. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325-337.

81. Adecka K, Rosen ST, Shammugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24:650-654.

82. Chen M, Zhang J, Manley JL. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 2010;70:8977-8980.

83. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(Suppl 5):4-9.

84. Taniguchi K, Sugito N, Kumazaki M, et al. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 2015;363:17-27.

85. Fujiya M, Konishi H, Mohamed Kamel MK, et al. microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. Oncogene. 2014;33:4847-4856.

86. Gull S, Caceres JF. The multifunctional RNA-binding protein hnrNPA1 is required for processing of miR-18a. Nat Struct Mol Biol. 2007;14:591-596.

87. Peitzsch C, Perrin R, Hill RP, et al. Hypoxia as a biomarker for radioresistance in colorectal cancer cells. Int J Radiat Biol. 2014;90:636-652.

88. Lin SC, Liao WL, Lee JC, Tsai SJ. Hypoxia-regulated gene network degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. Oncogene. 2014;33:8977-8980.

89. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.

90. Tagscherer KE, Fassl A, Sinkovic T, et al. MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen. Cancer Cell Int. 2016;16:42.

91. Wang W, Qu A, Liu W, et al. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. Eur J Cancer Care (Engl). 2017;26.
92. Sun Y, Xing X, Liu Q, et al. Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1alpha/miR-210/Bcl-2 pathway in colon cancer cells. Int J Oncol. 2015;46:750-756.

93. Kaminsky V, Zhivotovsky B. Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal. 2014;21:86-102.

94. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy. 2008;4:949-951.

95. Zhai Z, Wu F, Dong F, et al. Human autophagy gene ATG16L1 is post-transcriptionally regulated by MIR142-3p. Autophagy. 2014;10:468-479.

96. Lu C, Chen J, Xu H, et al. MIR106B and MIR93 prevent removal of microRNA-143 Targets ATG2B in autophagy by targeting ATG5/FIP200 in colorectal cancer. Mol Carcinog. 2019;58:1234-1247.

97. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.

98. Wang GF, Ren JA, Liu S, et al. Clinical characteristics of non-perianal fistulating Crohn's disease in China: a single-center experience of 184 cases. Chin Med J (Engl). 2012;125:2405-2410.

99. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease. Arch Biochem Biophys. 2020;595:599-610.

100. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol. 2016;14:111-119.

101. Tandon M, Othman AH, Ashok V, et al. The role of Runx2 in facilitating autophagy in metastatic breast cancer cells. J Cell Physiol. 2018;233:559-571.

102. Zhang P, Zhang H. Differential Expression of microRNAs in Peripheral Blood Mononuclear Cells Identifies Autophagy is post-transcriptionally regulated by MIR142-3p. Autophagy. 2014;10:468-479.

103. Lu C, Chen J, Xu H, et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology. 2014;146:188-199.

104. Mohamed A, Kelly OB, Filice M, et al. Differential Expression of microRNAs in Peripheral Blood Mononuclear Cells Identifies Autophagy and TGF-Beta-Related Signatures Aberrantly Expressed in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:568-581.

105. Nguyen HTT, Dalmasso G, Müller S, et al. Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology. 2014;146:508-519.

106. Fasseu M, Trétou X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5.

107. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.

108. Fujiwara H, Nishiumi S, Masuda A, et al. Autophagy in the intestinal epithelium reduces endotoxin-induced inflammatory responses by inhibiting NF-kappaB activation. Arch Biochem Biophys. 2011;506:223-235.

109. Lin X-T, Zheng X-B, Fan D-J, et al. MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease. Inflamm Bowel Dis. 2018;24:781-791.

110. Che J, Wang W, Huang YU, et al. miR-20a inhibits hypoxia-induced autophagy by targeting ATG5/FIP200 in colorectal cancer. Mol Carcinog. 2015;58:1234-1247.

111. Fujishima Y, Nishiumi S, Masuda A, et al. Calycosin induces apoptosis in adenocarcinoma HT29 cells by inducing cytotoxic autophagy mediated by SIRT1/AMPK-induced inhibition of Akt/mTOR. Clin Exp Pharmacol Physiol. 2019;46:944-954.

112. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

113. Zhang P, Zhang H. Autophagy modulates mRNA-mediated gene silencing and selectively degrades AIN-1/GW182 in C. elegans. Embo Rep. 2013;14:568-576.

114. Gibbings D, Mostowy S, Jay F, et al. Selective autophagy degrades Dicer and AGO2 and regulates mRNA activity. Nat Cell Biol. 2012;14:1314-1321.

115. Zhai Z, Wu F, Dong F, et al. Human autophagy gene ATG16L1 is post-transcriptionally regulated by MIR142-3p. Autophagy. 2014;10:468-479.

116. Liang YU, Zhu D, Zhu L, et al. Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway. J Cancer. 2019;10:6037-6047.

117. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22:124-131.

118. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

119. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

120. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

121. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

122. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

123. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

124. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

125. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

126. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

127. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

128. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

129. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

130. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.

131. Wang HX, Wang XY, Fei JW, et al. microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/B-catenin signaling pathway. J Biol Regul Homeost Agents. 2020;34.
134. El-Khider F, McDonald C. Links of Autophagy Dysfunction to Inflammatory Bowel Disease Onset. *Dig Dis.* 2016;34:27-34.

135. Gibbings D, Mostowy S, Voinnet O. Autophagy selectively regulates miRNA homeostasis. *Autophagy.* 2013;9:781-783.

136. Lan S-H, Wu S-Y, Zuchini R, et al. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. *Hepatology.* 2014;59:505-517.

137. Wampfler J, Federzoni EA, Torbett BE, et al. Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells. *J Leukoc Biol.* 2015;98:357-363.

138. Kovaleva V, Mora R, Park YJ, et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. *Cancer Res.* 2012;72:1763-1772.

**How to cite this article:** Long J, He Q, Yin Y, Lei X, Li Z, Zhu W. The effect of miRNA and autophagy on colorectal cancer. *Cell Prolif.* 2020;53:e12900. [https://doi.org/10.1111/cpr.12900](https://doi.org/10.1111/cpr.12900)